Chronic eye condition biotech SpyGlass Pharma files for a $100 million IPO
February 6, 2026 News
Chronic eye condition biotech SpyGlass Pharma prices IPO at $16 midpoint
SpyGlass Pharma, a Phase 3 biotech developing implanted drug-devices for chronic eye conditions, raised $150 million by offering 9.4 million shares at $16, the midpoint of the range of $15 to $17.
January 29, 2026 News
Chronic eye condition biotech SpyGlass Pharma sets terms for $150 million IPO
SpyGlass Pharma, a Phase 3 biotech developing implants to treat chronic eye conditions, announced terms for its IPO on Thursday.
The Aliso Viejo, CA-based company plans to raise $150 million by offering 9.4 million shares at a price range of $15 to $17. At the midpoint of the proposed range, SpyGlass Pharma would command a fully diluted market value of $549 million.
IPO Overview
SpyGlass Pharma, a phase 3 biotech developing implants to treat chronic eye conditions, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
SpyGlass Pharma is a late-stage biopharmaceutical company focused on chronic eye conditions by developing durable drug delivery solutions that provide long-term disease control and vision preservation. Its lead product candidate, the Bimatoprost Drug Pad-IOL System （BIM-IOL System）， comprising novel, proprietary drug pads attached to an intraocular lens （IOL）， is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure （IOP） in patients who have either open-angle glaucoma （OAG） or ocular hypertension （OHT）。 The BIM-IOL System is designed to consistently deliver three years of bimatoprost, a prostaglandin analog （PGA） approved for topical use by the U.S. Food & Drug Administration （FDA） in 2001 for the reduction of elevated IOP in patients with OAG or OHT. The company is also developing a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost, which it believes could be implanted in a standalone procedure, enable retreatment of patients who have received the BIM-IOL System, and offer extended care to patients with OAG or OHT who already received a prior cataract surgery.
The Aliso Viejo, CA-based company was founded in 2019 and plans to list on the Nasdaq under the symbol SGP. SpyGlass Pharma filed confidentially on September 26, 2025. Jefferies, Leerink Partners, Citi, and Stifel are the joint bookrunners on the deal. No pricing terms were disclosed.
About the Company
We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead product candidate, the Bimatoprost Drug Pad-IOL System （BIM-IOL System）， comprising novel, proprietary drug pads attached to our intraocular lens （IOL）， is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure （IOP） in patients who have either open-angle glaucoma （OAG） or ocular hypertension （OHT）。 The BIM-IOL System is designed to consistently deliver three years of bimatoprost, a prostaglandin analog （PGA） approved for topical use by the U.S. Food & Drug Administration （FDA） in 2001 for the reduction of elevated IOP in patients with OAG or OHT. We are also developing a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost, which we believe could be implanted in a standalone procedure, enable retreatment of patients who have received the BIM-IOL System, and offer extended care to patients with OAG or OHT who already received a prior cataract surgery （these patients who have had their IOLs replaced with artificial IOLs are referred to as pseudophakes or pseudophakic patients）。